» 
PharmNovo presenting at the Global Forum
Copy URL
https://www.pharmnovo.com/post/presentation-from-pharmnovo-at-the-global-forum

PharmNovo presenting at the Global Forum

June 5, 2024

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

PharmNovo is proud to participate in the premiere BioStock Global Forum in Lund on May 29-30. Don’t miss the opportunity to hear our CEO, Per von Mentzer, present the latest updates from PharmNovo.

Author:
Copy URL
https://www.pharmnovo.com/post/presentation-from-pharmnovo-at-the-global-forum

PharmNovo presenting at the Global Forum

June 5, 2024

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

PharmNovo is proud to participate in the premiere BioStock Global Forum in Lund on May 29-30. Don’t miss the opportunity to hear our CEO, Per von Mentzer, present the latest updates from PharmNovo.

Author:

Latest news

View all
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more
January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.

Read more